Search
Descriptor English: Mitolactol
Descriptor Spanish: Mitolactol
Descriptor mitolactol
Entry term(s) dibromodulcitol
Scope note: Agente alquilante antineoplásico, tóxico para la médula ósea; se utiliza en el cáncer de mama y en combinación con otros fármacos.
Descriptor Portuguese: Mitolactol
Descriptor French: Mitolactol
Entry term(s): Dibromodulcitol
NSC 104800
NSC-104800
NSC104800
Tree number(s): D02.033.800.400.500
D09.853.400.500
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D008936
Scope note: Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents, Alkylating
Registry Number: LJ2P1SIK8Y
CAS Type 1 Name: Galactitol, 1,6-dibromo-1,6-dideoxy-
Previous Indexing: Antineoplastic Agents (1966-1973)
Bromine (1966-1973)
Public MeSH Note: 81; was DIBROMODULCITOL 1974-80
Online Note: use MITOLACTOL to search DIBROMODULCITOL 1974-80
History Note: 81; was DIBROMODULCITOL 1974-80
DeCS ID: 9126
Unique ID: D008936
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1974/01/01
Date of Entry: 1999/01/01
Revision Date: 2013/07/08
Mitolactol - Preferred
Concept UI M0013947
Scope note Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs.
Preferred term Mitolactol
Entry term(s) Dibromodulcitol
NSC-104800 - Narrower
Concept UI M0350699
Preferred term NSC-104800
Entry term(s) NSC 104800
NSC104800



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey